MOUNTAIN VIEW, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that four companies have signed contracts for the Pharsight(R) Knowledgebase Server(TM) (PKS(TM)) Validation Suite ("PKS Validation Suite(TM)"). The new customers include two major pharmaceutical companies and two leading biopharmaceutical companies.
PKS Validation Suite enables rapid and reliable validation of Pharsight Knowledgebase Server (PKS) 3.0 installations using a combination of automated and manual tests. The Validation Suite provides templates for validation life cycle documents, such as a Validation Plan, Test Plan, and Validation Summary Report, and inserts automated test results into a Validation Run Report.
"The PKS Validation Suite streamlines the validation process for Pharsight's PKS product, resulting in a shorter path to the efficiencies and reliability advantages that PKS offers. The addition of four new customers is an important commercial milestone for the PKS Validation Suite. It is gratifying to see this newly-released product progress to commercial use in our PKS customer group," said Shawn O'Connor, Pharsight president and chief executive officer.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding trends in customer demand for Pharsight's products, services and technology, the anticipated development and performance of Pharsight's products and the expected benefits to customers from the use of Pharsight's products. Actual results may differ materially from Pharsight's expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight's products and services, changes in Pharsight's research and development focus or operating strategies, the failure to develop new products and services or to keep pace with technological changes, delays in the release of new products and services, the failure of Pharsight's products and services to obtain anticipated levels of customer acceptance or to meet customers' expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight, Pharsight Knowledgebase Server, PKS, and PKS Validation Suite are registered trademarks or trademarks of Pharsight Corporation.
Pharsight CorporationCONTACT: investors, Douglas Sherk, or Jennifer Beugelmans,+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, all of EVCGroup, for Pharsight Corporation
Web site: http://www.pharsight.com/
